Gastrointestinal stromal tumors (GISTs) are the most common sarcoma of the alimentary tract and are believed to derive from the interstitial Cell of Cajal. Imatinib mesylate (Gleevec; Novartis, Basel, Switzerland) has revolutionized the treatment of GISTs and is generally used in the metastatic and adjuvant settings. We report the case of a 61-year old man who was treated with neoadjuvant imatinib for a massive gastric GIST with the hope of avoiding a potential multi-visceral resection.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2661077 | PMC |
| http://dx.doi.org/10.1186/1477-7819-7-30 | DOI Listing |
Publication Analysis
Top Keywords
gastrointestinal stromal
8
dramatic response
4
response gastrointestinal
4
stromal tumor
4
tumor neadjuvant
4
neadjuvant imatinib
4
imatinib therapy
4
therapy gastrointestinal
4
stromal tumors
4
tumors gists
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!